|

Depemokimab Clinical Trials

6 actively recruiting trials across 6 locations

▲ +1 trial since August 2026

Also known as: GSK3511294

Pipeline

Phase 3: 6

Top Sponsors

  • GlaxoSmithKline6

Indications

  • Pulmonary Disease, Chronic Obstructive3
  • Asthma3
  • COPD3

Mobile, Alabama1 trial

A Study of Depemokimab in Participants of 6 to 11 Years of Age

GSK Investigational Site

Phase 3

Sheffield, Alabama1 trial

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

GSK Investigational Site

Phase 3

Little Rock, Arkansas1 trial

A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

GSK Investigational Site

Phase 3

Newport Beach, California1 trial

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

GSK Investigational Site

Phase 3

Brooksville, Florida1 trial

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

GSK Investigational Site

Phase 3

Loxahatchee Groves, Florida1 trial

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

GSK Investigational Site

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.